The global pharmaceutical fine chemicals market is expected
to reach USD 153.7 billion by 2025, according to a new report by Grand View
Research, Inc. Increasing demand for preventive healthcare is expected to be a
major factor driving market growth. Utilization of pharmaceutical fine
chemicals (PFCs) has increased on account of the increasing aging population
across the globe.
Cardiovascular is anticipated to
the fastest growing application segment over the over the next eight years
growing at an estimated CAGR of 8.4%. The occurrence of cardiovascular disease
is on the rise owing to the unhealthy lifestyle of human beings. According to
the World Health Organization (WHO), cardiovascular diseases are considered to
be the prime cause of fatalities across the globe. The organization also states
that cardiovascular diseases caused the death of approximately 17.7 million
people in the year 2015. This number approximately represented 31% of the total
deaths in the year 2015.
Obesity and an unhealthy
lifestyle are some of the most important factors which lead to the occurrence
of various diseases such as cardiovascular, neurological, oncological,
infectious diseases, metabolic system, diabetes, respiratory, gastrointestinal,
and musculoskeletal disorders. Eating junk food, leading unhygienic lifestyle,
irregular timetable and many other unhealthy habits lead to diseases amongst
human beings. Studies also show that males have more chance of contracting
diabetes as compared to females. All these factors combined are thus
anticipated to propel the market growth over the forecast period.
U.S. pharmaceutical fine
chemical market by application, 2014-2025 (USD Billion)
Browse full research report on
Pharmaceutical Fine Chemicals Market
Further key findings from the
report suggest:
- The global
pharmaceutical fine chemicals demand in terms of revenue was USD 78.2
billion in 2016 and is expected to grow at a CAGR of 7.9% from 2017 to
2025
- Proprietary
emerged as the largest type segment in 2016 and is estimated to generate
revenue of USD 125.1 billion by 2025
- Big molecules
were the largest size segment in 2016 and is expected to grow at an estimated
CAGR of 7.8% over the next eight years
- Advanced
intermediates is expected to be the fastest growing product segment over
the forecast period growing at an estimated CAGR of 8.3%
- Industry
participants include Angelini Acraf S.p.A, Albermarle Corporation, Chemada
Fine Chemicals, W.R. Grace & Co., and Kenko Corporation. These players
have vertically integrated their operations to increase their market
presence and thus gain competitive advantage in the market
About Grand View Research,
Inc:
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For more information: http://www.grandviewresearch.com
No comments:
Post a Comment